Principal Financial Group Inc. Purchases 12,624 Shares of Illumina, Inc. $ILMN

Principal Financial Group Inc. raised its position in Illumina, Inc. (NASDAQ:ILMN) by 3.8% during the first quarter, according to its most recent filing with the SEC. The firm owned 341,244 shares of the life sciences company’s stock after purchasing an additional 12,624 shares during the period. Principal Financial Group Inc.’s holdings in Illumina were worth $42,062,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. 180 Wealth Advisors LLC lifted its holdings in Illumina by 0.4% in the first quarter. 180 Wealth Advisors LLC now owns 34,617 shares of the life sciences company’s stock valued at $4,267,000 after buying an additional 133 shares during the period. Citizens Financial Group Inc. RI grew its holdings in Illumina by 18.7% during the 1st quarter. Citizens Financial Group Inc. RI now owns 3,055 shares of the life sciences company’s stock worth $377,000 after acquiring an additional 481 shares during the period. Fifth Third Bancorp grew its holdings in Illumina by 2,880.0% during the 1st quarter. Fifth Third Bancorp now owns 42,375 shares of the life sciences company’s stock worth $5,223,000 after acquiring an additional 40,953 shares during the period. Candriam S.C.A. bought a new position in shares of Illumina in the 1st quarter worth about $12,533,000. Finally, Sequoia Financial Advisors LLC raised its position in shares of Illumina by 19.6% in the 1st quarter. Sequoia Financial Advisors LLC now owns 8,128 shares of the life sciences company’s stock worth $1,002,000 after acquiring an additional 1,331 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Insider Transactions at Illumina

In other news, SVP Patricia Leckman sold 783 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the sale, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total value of $110,700.00. Following the sale, the insider owned 20,953 shares of the company’s stock, valued at approximately $3,771,540. This represents a 2.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,003,769 shares of company stock worth $155,710,908. 2.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several research analyst reports. Barclays upped their target price on Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a research report on Wednesday, June 24th. Piper Sandler lifted their target price on Illumina from $170.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 1st. Citigroup boosted their price target on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Thursday, May 14th. Finally, Evercore reaffirmed an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Nine research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $156.88.

Illumina Price Performance

ILMN stock opened at $186.65 on Friday. The stock has a market capitalization of $28.24 billion, a PE ratio of 33.94, a price-to-earnings-growth ratio of 3.49 and a beta of 1.47. The company’s 50-day moving average is $166.44 and its 200-day moving average is $143.34. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $196.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the company posted $0.97 EPS. The firm’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts expect that Illumina, Inc. will post 5.22 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.